Clinical Trial

A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-07-19
notable Enrollment increased: 1978 -> 5386 participants 2026-07-19
Trial Details
NCT Number NCT07419828
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Chronic Kidney Disease
Enrollment 5,386 participants
Start Date 2026-03-13
Primary Completion 2030-04 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-17